We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00117572
Recruitment Status : Unknown
Verified October 2012 by Ezra Cohen, MD, University of Chicago.
Recruitment status was:  Active, not recruiting
First Posted : July 7, 2005
Last Update Posted : October 10, 2012
Information provided by (Responsible Party):
Ezra Cohen, MD, University of Chicago

Brief Summary:
The combined use of chemotherapeutic drugs with radiation has proven to be effective in improving overall survival and local control among patients with locally advanced head and neck cancer. Induction chemotherapy given before receiving local treatment has been shown to reduce the rate of distant failure. Many drugs have been found to prevent tumor cells from growing or dividing, although it has yet to be determined which agent, or specific combination of agents, is most effective in treating head and neck cancer. Docetaxel is a drug which has been reported to show promising activity in Phase II head and neck cancer studies. Therefore, the purpose of this trial is to compare the effectiveness of induction chemotherapy followed by chemoradiotherapy versus the same chemoradiotherapy alone in patients with locally advanced head and neck cancer.

Condition or disease Intervention/treatment Phase
Cancer of the Pharynx Cancer of the Larynx Cancer of the Nasal Cavity Paranasal Sinus Neoplasms Cancer of the Oral Cavity Drug: docetaxel Drug: cisplatin Drug: hydroxyurea Drug: fluorouracil Procedure: chemotherapy Procedure: radiotherapy Phase 3

Detailed Description:


Phase III trial of induction therapy with docetaxel followed by chemoradiotherapy versus chemoradiotherapy alone in patients with nodal stage N2 or N3 head and neck cancer



  • To determine the effect on overall survival when induction chemotherapy is administered prior to chemoradiotherapy in patients with N2 or N3 disease.


  • To determine the effect of induction chemotherapy when administered prior to chemoradiotherapy on distant failure-free survival, failure pattern, progression free survival and quality of life.


  • After eligibility is confirmed, patients will be randomized to one of two treatment arms:

Arm A - Induction + chemoradiotherapy

Arm B - Chemoradiotherapy alone

  • Induction therapy: Two 21-day cycles of chemotherapy consisting of docetaxel (day 1), cisplatin (day 1), and 5-fluorouracil (days 1-5). Total duration of 6 weeks.
  • Chemoradiotherapy: Five 14-day cycles of docetaxel (day 1), 5-fluorouracil (day 0-4), and hydroxyurea (days 0-4) with twice daily radiation (days 1-5). Total duration of 10 weeks.
  • All patients will undergo surgical evaluation after chemoradiation for possible neck dissection.
  • Upon completion of treatment, patients will be monitored every three months during the first year, every six months during the second and third years, and annually thereafter, up to five years.
  • Patients will be followed for Quality of Life (QOL) during the course of treatment, as well as annually thereafter, up to five years.


  • An expected sample size of 400 patients will be enrolled for this study (200 per treatment arm).

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Study Start Date : November 2004
Primary Completion Date : May 2009
Estimated Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1 Drug: docetaxel
75 mg/m2 on day 1
Drug: cisplatin
75 mg/m2 on day 1
Drug: hydroxyurea
Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
Drug: fluorouracil
750 mg/m2/day on days 1-5 of induction
Procedure: chemotherapy
See protocol for details
Procedure: radiotherapy
See protocol for details
Active Comparator: 2 Drug: hydroxyurea
Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
Procedure: chemotherapy
See protocol for details
Procedure: radiotherapy
See protocol for details

Primary Outcome Measures :
  1. Overall survival [ Time Frame: Indefinitely ]

Secondary Outcome Measures :
  1. Distant failure-free survival (DFFS) [ Time Frame: Indefinitely ]
  2. failure pattern [ Time Frame: Indefinitely ]
  3. progression free survival [ Time Frame: Indefinitely ]
  4. quality of life (QOL) [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or older
  • Histologically or cytologically confirmed diagnosis of squamous cell or poorly differentiated carcinomas of the head and neck (excluding lip), or lymphoepithelioma
  • No prior chemotherapy or radiotherapy
  • Prior surgical therapy will consist only of incisional or excisional biopsy, and organ sparing procedures such as debulking of airway-compromising tumors or neck dissection in a patient with an existing primary tumor
  • Karnofsky performance status of >= 70%
  • Intact organ and bone marrow function
  • Obtained informed consent

Exclusion Criteria:

  • Demonstration of metastatic disease (i.e. M1 disease).
  • Patients with a history of severe allergic reaction to docetaxel or other drugs formulated with polysorbate 80. History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, 5-fluorouracil, or hydroxyurea
  • Other coexisting malignancies or malignancies diagnosed within the previous 3 years with the exception of basal cell carcinoma, cervical cancer in situ, and other treated malignancies with no evidence of disease for at least 3 years.
  • Prior surgical therapy other than incisional or excisional biopsy and organ-sparing procedures such as debulking of airway-compromising tumors or neck dissection in a patient with an unknown primary tumor. Any non-biopsy procedure must have taken place less than 3 months from initiating protocol treatment.
  • Incomplete healing from previous surgery
  • Pregnancy or breast feeding (men and women of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least 3 months after completing therapy)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any history of clinically significant CHF are excluded. The exclusion of patients with active coronary artery disease will be at the discretion of the attending physician.
  • Uncontrolled active infection unless curable with treatment of their cancer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00117572

United States, California
USC University of Southern California Keck School of Medicine
Los Angeles, California, United States, 90033
United States, Florida
UM Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Rush University Medical Center
Chicago, Illinois, United States, 60612
The University of Chicago
Chicago, Illinois, United States, 60637
Weiss Memorial Hospital
Chicago, Illinois, United States, 60640
Evanston Northwestern Healthcare
Evanston, Illinois, United States, 60201
Joliet Oncology Hematology Associates
Joliet, Illinois, United States, 60435
United States, Indiana
Fort Wayne Medical Oncology/Hematology Inc.
Fort Wayne, Indiana, United States, 46815
AP&S Clinic, LLC
Terre Haute, Indiana, United States, 47807
United States, Kansas
University of Kansas Cancer Center
Kansas City, Kansas, United States, 66160
United States, Michigan
Henry Ford Health System
Detroit, Michigan, United States, 48202
Oncology Care Associates PLLC
St. Joseph, Michigan, United States, 49085
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Kansas City VA Medical Center
Kansas City, Missouri, United States, 64128
United States, North Dakota
Roger Maris Cancer Center
Fargo, North Dakota, United States, 58122
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
United States, Tennessee
University of Tennessee Cancer Institute
Memphis, Tennessee, United States, 38104
United States, Texas
UT Health Science Center at San Antonio
San Antonio, Texas, United States, 78258
United States, Wisconsin
Oncology Alliance
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
University of Chicago
Principal Investigator: Everett E. Vokes, M.D. University of Chicago
Principal Investigator: Ezra E.W. Cohen, M.D. University of Chicago

Responsible Party: Ezra Cohen, MD, Associate Prof of Medicine, University of Chicago
ClinicalTrials.gov Identifier: NCT00117572     History of Changes
Other Study ID Numbers: 13362B
First Posted: July 7, 2005    Key Record Dates
Last Update Posted: October 10, 2012
Last Verified: October 2012

Keywords provided by Ezra Cohen, MD, University of Chicago:
Cancer of the Pharynx (Nasopharynx, Oropharynx, Hypopharynx)
Cancer of the Nasal Cavity and Paranasal Sinuses

Additional relevant MeSH terms:
Paranasal Sinus Neoplasms
Head and Neck Neoplasms
Laryngeal Neoplasms
Pharyngeal Neoplasms
Neoplasms by Site
Otorhinolaryngologic Neoplasms
Laryngeal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Otorhinolaryngologic Diseases
Nose Neoplasms
Nose Diseases
Paranasal Sinus Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antisickling Agents